Northvale, New Jersey--(Newsfile Corp. - August 14, 2024) - Elite Pharmaceuticals, Inc. (OTCQB: ELTP) ("Elite" or the "Company"), a specialty pharmaceutical company engaged in the development, manufacture, and distribution of niche generic products, announced results for the three months ended June 30, 2024, which is the first quarter of the Company's fiscal year ending on March 31, 2025 ("First Quarter").
Consolidated revenues for the three-month period ended June 30, 2024, were $18.8 million, an increase of $9.8 million or approximately 109% as compared to the comparable period of the prior fiscal year. Operating profits were $3.9 million, an increase of $2.3 million or approximately 144%, as compared to the comparable period of the prior fiscal year, and net income attributable to common shareholders was $0.6 million. The increase in operating profits was primarily attributed to higher level of sales achieved by the Elite label product line during the quarter ended June 30, 2024, as compared to the comparable period of the prior year.
Conference Call Information
Elite's management will host a conference call to discuss the First Quarter financial results and provide an update on recent business developments. Stockholder questions should be submitted to the company in advance of the call.
Date: | August 15, 2024 |
Time: | 11:30 AM EDT |
Dial-in numbers: | 1-800-346-7359 (domestic) 1-973-528-0008 (international) |
Conference number: | 98840 |
Questions: | This email address is being protected from spambots. You need JavaScript enabled to view it. Financial questions by 7:00 PM EDT on Wednesday, August 14, 2024 |
Audio Replay: | https://elite.irpass.com/events_presentations |
The financial statements can be viewed for Elite's First Quarter of Fiscal Year 2025 on Form 10-Q here.
About Elite Pharmaceuticals, Inc.
Elite Pharmaceuticals, Inc. is a specialty pharmaceutical company that develops and distributes niche generic products. Elite specializes in developing and manufacturing oral, controlled-release drug products. Elite owns multiple generic products, some of which are licensed to Prasco, LLC and TAGI Pharma. Elite operates a cGMP and DEA-registered facility for research, development, and manufacturing located in Northvale, NJ. For more information, visit www.elitepharma.com.
This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including, without limitation, those related to the effects, if any, on future results, performance or other expectations that may have some correlation to the subject matter of this press release. Readers are cautioned that such forward-looking statements involve, without limitation, risks, uncertainties and other factors not under the control of Elite, which may cause actual results, performance or achievements of Elite to be materially different from the results, performance or other expectations that may be implied by these forward-looking statements. These forward-looking statements may include statements regarding the expected timing of approval, if at all, of products by the FDA, and the actions the FDA may require of Elite in order to obtain such approvals. These forward-looking statements are not guarantees of future action or performance. These risks and other factors are discussed, without limitation, in Elite's filings with the Securities and Exchange Commission, including its reports on forms 10-K, 10-Q, and 8-K. Elite is under no obligation to update or alter its forward-looking statements, whether as a result of new information, future events or otherwise.
Contact:
For Elite Pharmaceuticals, Inc.
Dianne Will, Investor Relations, 518-398-6222
This email address is being protected from spambots. You need JavaScript enabled to view it.
www.elitepharma.com
Last Trade: | US$0.50 |
Daily Change: | 0.05 11.24 |
Daily Volume: | 808,331 |
Market Cap: | US$529.650M |
October 10, 2024 October 07, 2024 |
Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MOREC4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB